EGFR Exon 19 Deletion Mutation

DrugDrug NameDrug Description
DB11963DacomitinibDacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains.[A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018.[L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model[A39624], although further investigations are needed.
DrugDrug NamePhaseStatusCount
DB12340Navitoclax1Recruiting1
DB09559Necitumumab1Recruiting1
DB09330Osimertinib1Recruiting3
DB11836Sapanisertib1Recruiting1
DB09330Osimertinib1 / 2Recruiting1
DB15232Telaglenastat1 / 2Recruiting1
DB00112Bevacizumab2Active Not Recruiting1
DB00112Bevacizumab2Recruiting1
DB00530Erlotinib2Active Not Recruiting1
DB09330Osimertinib2Recruiting1
DB00530Erlotinib3Recruiting1